Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA227865-01A1)
Received: 19 March 2021
Accepted: 2 May 2022
First Online: 9 June 2022
: R.G. is an inventor on multiple issued patents and patent applications covering the manufacture and use of 3DNA technology as part of his role in Code Biotherapeutics, Inc. He is also an employee and officer of Code Biotherapeutics, Inc. and has stock and stock options. C.A.L. has received consulting fees from Astellas Pharmaceuticals and Odyssey Therapeutics and is an inventor on patents pertaining to Kras-regulated metabolic pathways, redox control pathways in cancer and targeting of the GOT1-pathway as a therapeutic approach. J.M.S. is a coauthor on patents on IDH1 inhibitors, and has received sponsored research funding from the Barer Institute and patents pending to Wistar Institute. J.M.W., along with University Hospitals, filed the following patent application on 24 September 2020: Methods for Treating Wild Type Isocitrate Dehydrogenase 1 Cancers. Information regarding this patent application is as follows: PCT/US20/52445 filed 24 September 2020, Claiming Priority to US 62/911,717 filed 7 October 2019, file nos: UHOSP-19738 | 2019-014.